Rebamipide and its Use in Clinical Practice (Literature Review, Meta-Analysis and Our Experience), Part I. Preventive and Therapeutic Effect of Rebamipide in NSAID-Induced Gastroenteropathies
Boris D. Starostin
Abstract
Introduction: In clinical practice, the prevalence of NSAID-induced damage to the esophagus, stomach, and intestines is of great importance, as it is dangerous for the occurrence of significant bleeding, sometimes leads to death, requires huge material costs, significantly disrupts the quality of life of patients. Gastroenteroprotector rebampide has been widely used in the treatment of a wide range of diseases of the gastrointestinal tract and its special position in the prevention and treatment of NSAID-induced damage to the gastrointestinal tract. However, there are some questions to the evidence base.
Aim: Our work was to analyze the available data on the use of rebamipide in the prevention and treatment of NSAID-induced esophagogastroenteropathy from the perspective of evidence-based medicine.
Methods: A search through various databases for randomized controlled studies on the use of rebamipide as monotherapy or in combination with an PPI or hystamine H2-receptor blocker revealed 24 studies. A meta-analysis of the use of rebamipide for the prevention and treatment of NSAID-induced esophagogastroenteropathy was conducted. In addition, a review and analysis of the available meta-analyses of the use of rebamipide and the assessment of its effectiveness in comparison with other drugs in terms of efficacy and safety were conducted.
Conclusions: our meta-analysis proved the efficacy and safety of rebamipide in the prevention and treatment of gastrointestinal injuries caused by the use of NSAIDs, which was also confirmed by previous meta-analyses and certain recommendations and consensus of various communities of specialists dealing with this problem.
